- BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
- BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
- BeiGene Reports First Quarter 2024 Financial Results and Business Updates
- BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
More ▼
Key statistics
On Friday, Beigene Ltd (6160:HKG) closed at 88.55, 17.36% above the 52 week low of 75.45 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 93.70 |
---|---|
High | 94.85 |
Low | 88.55 |
Bid | 88.55 |
Offer | 88.70 |
Previous close | 90.40 |
Average volume | 1.35m |
---|---|
Shares outstanding | 1.36bn |
Free float | 1.29bn |
P/E (TTM) | -- |
Market cap | 125.26bn HKD |
EPS (TTM) | -4.55 HKD |
Data delayed at least 15 minutes, as of May 31 2024 09:08 BST.
More ▼